This document is page 11 of a confidential presentation (likely an investment prospectus for 'NLV-III') detailing the history and senior team of New Leaf Ventures. It features a timeline of funds raised from 1993 to 2007 under Sprout and New Leaf brands, totaling billions in capital. The page highlights the biography of Managing Director Philippe Chambon, detailing his history with Sprout, Boston Consulting Group, and Sandoz Pharmaceutical, as well as his numerous board memberships in the healthcare and biotech sectors. The document bears a House Oversight Committee control number.
This document is a financial appendix page (marked CONFIDENTIAL) bearing a House Oversight Bates stamp (HOUSE_OVERSIGHT_024103). It details the investment performance of 'Sprout Capital VIII, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It lists specific investments in healthcare and technology companies (such as Charles River Laboratories and eHealth, Inc.), showing the vintage year (ranging from 1998-2000), total cost, realized value, and internal rate of return (IRR) for each.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity